Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Again you are incorrect when a company is under attack the do what they need to to get facts out some a little earlier then they previously wanted. There has been boring nothing out of the ordinary to other successful companies that went through these types of issues. The fact that you only compare the company to the failed ones when there are plenty that didn't fail but had to do the same to survive really puts comments low on the radar for real investors!
Company never offers a bounty. The rest will be proven as false with the quarter and annual reporting.
Glad Leo is in charge! Keeping the company running with no worry of SP to keep the trials going... Genius!!! Very little dilution over the years to what has been accomplished! I am so happy I rely on my own DD over the other option as of late here!!!
Drugs moving well through trials! Exciting times for sure!!!
GLTA
Glad Leo is in charge! Keeping the company running with no worry of SP to keep the trials going... Genius!!! Very little dilution over the years to what has been accomplished! I am so happy I rely on my own DD over the other option as of late here!!!
Drugs moving well through trials! Exciting times for sure!!!
GLTA
This comment is so inaccurate it is hilarious... The company is set for a few more quarters with cash on hand and that would be if they haven't cashed in any of the $30 million available.. Dilution has been a very minimal issue as we have ramped up heavily on trials. There is no concern to need a partner for less than great terms...
To be expected immediate down playing of any news.. by the same suspects!
This is good news if your not sure wait for some of the smarter (smarter than me) people to lay it out in laymen terms! This is good stuff!
GLTA
2 reasons one the author of the article says he is a short. And two Because I said so!
Looks like we are back to this point in the cycle... Rebound time.. looks like that old song my mom use to sing to me.... send in the clowns!
GLTA
Noticing a lot more negative posts about long term share holders and splits and rather insignificant stuff. All the negative science gets pushed back immediately and has more recently become less...
Long term investors are not selling. They have dried that well up... Does seems as though the nerves are getting the better of them and they are getting ready to jump ship and move on.
They haven't been able to discredit the management or the drugs, as hard as they have tried. The fear is going away and we are filling with new stronger hands and the longs are adding!
IMHO of course
GLTA
Once Cellceutix up-lists don't they have to have there own MMs in place? Why can't they set that up now?
GLTA
Good luck to all the longs! Next few weeks should get exciting!
Someone with big connections need to drop his 600 shares in small increments at the same price under the bid and 11 cents under previous close... Not sure how that would make any sense seeing as how it opened 4 cents above that.... Not a very good connection!!!
So since the MMs manipulated the price in the pre market selling shares under the bid to drive the price down that makes the charts accurate?
TIA
GLTA
Credibility of management has been proven! They have rebutted all the false claims and their accomplishments in the trials moving forward regardless of the false attacks show an amazing attitude to see these drugs get to people that need them!!!
Claiming the value of the company will only be supported by BIG news is ridiculous! They have announce huge news since being above this price and is clearly been under attack. There are not scaring longs anymore they are locked up... only people buying now are stronger hands and less than 1% of the total shares are being traded between what ever group or groups are out there playing around with it...
They wont be able to keep it up. The value of the company is way above current SP and it will be hard to maintain this low level by any group!!!
GLTA
Good catch Karin! Usually takes a couple of days for trials to update the information so they are probably already setting the new patients up!!!
GLTA
Thanks for your relentless research and great updates on these trials as they advance!!!
GLTA
In pre market and first few minutes there were a lot of shares sold under the bid... that's how they dropped it so fast.
In pre market and first few minutes there were a lot of shares sold under the bid... that's how they dropped it so fast.
Couple of them MMs are working real hard for someone this morning!!!
Definitely looks a chance for a green day. Looking at the charts and the boards. May see that early morning push down that they like to do to discourage new investors, but as we gather more intellectual investors the shares will be held in the better stronger hands!!!
Making any short squeeze(if there is one, and is a good chance) look like a rocket ship.
GLTA
"Look at this way - the B Has taken around 1 year from P2b results and possible start of ph 3 trial"
Could you please tell me the where you have seen other antibiotics move quicker through the process please... The fact that B is approved for P3 is amazing enough information to value this stock at a much higher price. This is based on facts of other run ups based on trial progression!
"The actual trial could take another 1 year - K is touching 3rd year in Ph I"
Do you realize the benefit of what was accomplished over those that time frame as opposed to a rushed P1 falling becasue the over looked something (you know like Poly did with B).. and it is not going to take another year lol
I am pretty confident that if 1/2% of the shares have left weaker hands it does not say anything about over confidence in the company be it drugs or management!!
GLTA
I think all longs are going to be very happy very soon if progression stays on track!
GLTA
My confusion is the statement people are throwing around that "the market" is showing it's feeling about management etc etc... Less than 1% of the shares are being passed back and fourth... That doesn't seem like a "market" decision is being made by any means!!!
As the science moves forward the price will re correct. All it seems like is there are more short term traders playing the swings than long term investors being shaken out... IMHO
GLTA
Q3 Milestones / Upcoming Catalysts
- Start of B-ABSSSI (Phase 3)
(your comment)This will not occur in Q3. We'll be luck if this is under way in Q4. More likely to begin Q1 2016.
*Your opinion and inaccurate
- Start of K + cytarabine (Phase 2)
(your comment)I was unclear if this could begin before K P1 is wrapped up.
*Cleary been stated that this can start before phase 1 completion.
- Completion of K (Phase 1)
(your comment)This is a Q4 event to finish. We'll be into Q1 2016 before all the data is compiled.
*You are incorrect again as was stated they hope to be wrapped up anytime now.
- 10-K (mid-September)
(your comment)True. Nothing too interesting here.
*This will trigger uplist
- NASDAQ uplisting
(your comment)With the 10K, we seem unable to hold $2. A reverse split may be necessary.
*we? haha It wont take that much to push back above $2 once the pressure is on. The false negative articles are already loosing their ability to influence investors. all that's left is to cover! Probably go by $2 so quick half this board will just post emoticons!
Q3 Milestones / Upcoming Catalysts
- Start of B-ABSSSI (Phase 3)
- Start of K + cytarabine (Phase 2)
- Completion of K (Phase 1)
- 10-K (mid-September)
- NASDAQ uplisting
Past Milestones
- QIDP designation for B-ABSSSI
- K orphan drug designation for ovarian cancer
- Start of B-OM (Phase 2)
- Start of P (Phase 2)
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P (Phase 1) primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)
Clinical Trials
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1
1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
I highly doubt that many longs have sold out. They try to make the tape look like people are selling... but its just noise. I am sure there are many trying to play the swings selling back and fourth to each other but not even 1% of shares are being moved around. So there really isn't much concern to myself as a long still holding all my shares!
Cellceutix.Com for your most up to date FACTUAL information.
Q3 Milestones / Upcoming Catalysts
- Start of B-ABSSSI (Phase 3)
- Start of K + cytarabine (Phase 2)
- Completion of K (Phase 1)
- 10-K (mid-September)
- NASDAQ uplisting
Past Milestones
- QIDP designation for B-ABSSSI
- K orphan drug designation for ovarian cancer
- Start of B-OM (Phase 2)
- Start of P (Phase 2)
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P (Phase 1) primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)
Clinical Trials
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1
1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
Above from following post: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116090505&txt2find=catalyst
GLTA
The fact is the numbers are inaccurate as to what people are saying they are. They are not short intrests they are short term positions.... the numbers are irrelevant they they are being used
GLTA
Please do disclose to all of us whom these analysts are. I'm curios as there are no know to be analysts covering ctix excrpt a couple self proclained shorts on SA, they don't count as analysts bag on the stated position! TIA
CTIX is grossly oversold and actually had a huge buy rating based on potential value of drugs moving very well through trials. The company is way ahead of many way more pricey stocks.
GLTA
Q3 Milestones / Upcoming Catalysts
- Start of B-ABSSSI (Phase 3)
- Start of K + cytarabine (Phase 2)
- Completion of K (Phase 1)
- 10-K (mid-September)
- NASDAQ uplisting
Past Milestones
- QIDP designation for B-ABSSSI
- K orphan drug designation for ovarian cancer
- Start of B-OM (Phase 2)
- Start of P (Phase 2)
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P (Phase 1) primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)
Clinical Trials
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1
1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
Anyone else not seeing any trades in over 1 hour?
Thank you for sharing.... sounds like good times are not far away. I'm excited to see Kevetrin coming along. I can't wait until it's saving many lives!
My understanding he was referring to Leo's opinion on valuation of certain sucess.
GLTA
No manipulation, MMs don't do that, it's in your head? Look at the time/sales for the last 15 minutes.... straight manipulation! That's all!
It's an illusion. If you watch the way the time/sales go is the MMs trying to make it look like people are selling into the bid, they are actually buys at .1 below the ask. It's manipulating at its finest. I'm not selling!
GLTA
Prurisol trial firing in all cylinders out the gate multiple sites up and recruiting.... 16 weeks per person. Phase 2 could easily be completed by December! B-OM could be finishing up to...
GLTA
Catalyst!
Re-Posting:
Q3 Milestones / Upcoming Catalysts
- Start of B-ABSSSI (Phase 3)
- Start of K + cytarabine (Phase 2)
- Completion of K (Phase 1)
- 10-K (mid-September)
- NASDAQ uplisting
Past Milestones
- QIDP designation for B-ABSSSI
- K orphan drug designation for ovarian cancer
- Start of B-OM (Phase 2)
- Start of P (Phase 2)
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P (Phase 1) primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)
Clinical Trials
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1
1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
Actually you are very incorrect. The big shorts cleared out. They may try back again in 6-8 months if expected catalysts aren't hit.... there is a very small weak group left and they are active on this board as they were before the big boys jumped in and did this damage, the input thing is the small shorts think they have another one and more time... don't think that's going to happen.
Why are you invested here? Just curious...
GLTA
Catalyst shouldn't get lost in the shuffle!
Re-Posting:
Q3 Milestones / Upcoming Catalysts
- Start of B-ABSSSI (Phase 3)
- Start of K + cytarabine (Phase 2)
- Completion of K (Phase 1)
- 10-K (mid-September)
- NASDAQ uplisting
Past Milestones
- QIDP designation for B-ABSSSI
- K orphan drug designation for ovarian cancer
- Start of B-OM (Phase 2)
- Start of P (Phase 2)
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P (Phase 1) primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)
Clinical Trials
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1
1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
They wouldn't let my trade go through for 2.01 in the last 4 minutes of the day.... they're weren't letting it go over 2!
GLTA